Tumour therapy with radionuclides: assessment of progress and problems
(2003) In Radiotherapy and Oncology 66(2). p.107-111- Abstract
- Radionuclide therapy is a promising modality for treatment of tumours of haematopoietic origin while the success for treatment of solid tumours so far has been limited. The authors consider radionuclide therapy mainly as a method to eradicate disseminated tumour cells and small metastases while bulky tumours and large metastases have to be treated surgically or by external radiation therapy. The promising therapeutic results for haematological tumours give hope that radionuclide therapy will have a breakthrough also for treatment of disseminated cells from solid tumours. New knowledge related to this is continuously emerging since new molecular target structures are being characterised and the knowledge on pharmacokinetics and cellular... (More)
- Radionuclide therapy is a promising modality for treatment of tumours of haematopoietic origin while the success for treatment of solid tumours so far has been limited. The authors consider radionuclide therapy mainly as a method to eradicate disseminated tumour cells and small metastases while bulky tumours and large metastases have to be treated surgically or by external radiation therapy. The promising therapeutic results for haematological tumours give hope that radionuclide therapy will have a breakthrough also for treatment of disseminated cells from solid tumours. New knowledge related to this is continuously emerging since new molecular target structures are being characterised and the knowledge on pharmacokinetics and cellular processing of different types of targeting agents increases. There is also improved understanding of the factors of importance for the choice of appropriate radionuclides with respect to their decay properties and the therapeutic applications. Furthermore, new methods to modify the uptake of radionuclides in tumour cells and normal tissues are emerging. However, we still need improvements regarding dosimetry and treatment planning as well as an increased knowledge about the tolerance doses for normal tissues and the radiobiological effects on tumour cells. This is especially important in targeted radionuclide therapy where the dose rates often are lower than 1 Gy/h. (C) 2002 Elsevier Science Ireland Ltd. All rights reserved. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/306962
- author
- Carlsson, J ; Aronsson, EF ; Hietala, SA ; Stigbrand, T and Tennvall, Jan LU
- organization
- publishing date
- 2003
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- tumour therapy, radionuclide therapy, effects, radiation, metastasis, disseminated tumour cells, low dose rate, review
- in
- Radiotherapy and Oncology
- volume
- 66
- issue
- 2
- pages
- 107 - 111
- publisher
- Elsevier
- external identifiers
-
- wos:000183860000001
- pmid:12648782
- scopus:0037295293
- ISSN
- 1879-0887
- DOI
- 10.1016/S0167-8140(02)00374-2
- language
- English
- LU publication?
- yes
- id
- 9d6ba30c-9979-42f3-881b-f93e2822cfd5 (old id 306962)
- date added to LUP
- 2016-04-01 12:21:36
- date last changed
- 2022-01-27 02:43:03
@article{9d6ba30c-9979-42f3-881b-f93e2822cfd5,
abstract = {{Radionuclide therapy is a promising modality for treatment of tumours of haematopoietic origin while the success for treatment of solid tumours so far has been limited. The authors consider radionuclide therapy mainly as a method to eradicate disseminated tumour cells and small metastases while bulky tumours and large metastases have to be treated surgically or by external radiation therapy. The promising therapeutic results for haematological tumours give hope that radionuclide therapy will have a breakthrough also for treatment of disseminated cells from solid tumours. New knowledge related to this is continuously emerging since new molecular target structures are being characterised and the knowledge on pharmacokinetics and cellular processing of different types of targeting agents increases. There is also improved understanding of the factors of importance for the choice of appropriate radionuclides with respect to their decay properties and the therapeutic applications. Furthermore, new methods to modify the uptake of radionuclides in tumour cells and normal tissues are emerging. However, we still need improvements regarding dosimetry and treatment planning as well as an increased knowledge about the tolerance doses for normal tissues and the radiobiological effects on tumour cells. This is especially important in targeted radionuclide therapy where the dose rates often are lower than 1 Gy/h. (C) 2002 Elsevier Science Ireland Ltd. All rights reserved.}},
author = {{Carlsson, J and Aronsson, EF and Hietala, SA and Stigbrand, T and Tennvall, Jan}},
issn = {{1879-0887}},
keywords = {{tumour therapy; radionuclide therapy; effects; radiation; metastasis; disseminated tumour cells; low dose rate; review}},
language = {{eng}},
number = {{2}},
pages = {{107--111}},
publisher = {{Elsevier}},
series = {{Radiotherapy and Oncology}},
title = {{Tumour therapy with radionuclides: assessment of progress and problems}},
url = {{http://dx.doi.org/10.1016/S0167-8140(02)00374-2}},
doi = {{10.1016/S0167-8140(02)00374-2}},
volume = {{66}},
year = {{2003}},
}